Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperandrogenism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Hyperandrogenism. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-004100-35 Sponsor Protocol Number: FSJD-PIOSPIMET-2012 Start Date*: 2012-12-20
    Sponsor Name:Fundació per la Recerca i la Docència Sant Joan de Déu
    Full Title: A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglit...
    Medical condition: Ovarian hyperandrogenism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005092-24 Sponsor Protocol Number: FSJD-PIOSPIMET-2015 Start Date*: 2016-01-22
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglit...
    Medical condition: ovarian hyperandrogenism with hyperinsulinaemia
    Disease:
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004163-39 Sponsor Protocol Number: HSJD-LIT-05 Start Date*: 2005-11-14
    Sponsor Name:Hospital Sant Joan de Déu
    Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ...
    Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000677-77 Sponsor Protocol Number: S61338 Start Date*: 2018-06-26
    Sponsor Name:University Hospital Leuven
    Full Title: Novel strategies in weight loss in women with polycystic ovary syndrome: does the gut microbiome play a role?
    Medical condition: overweight and obese women with polycystic ovary syndrome (PCOS) at risk for metabolic syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004257-26 Sponsor Protocol Number: 160350 Start Date*: 2005-02-28
    Sponsor Name:Organisation name was not entered
    Full Title: A randomised study of the effect of metformin and exercise in overweight women with polycystic ovary syndrome
    Medical condition: Polycystic ovary syndrome is a condition characterized by obesity, anovulation and hyperandrogenism/hyperandrogenemia. Insulin resistance is common, and treatment is aimed at reducing this.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001124-20 Sponsor Protocol Number: PCOS-5 Start Date*: 2005-04-18
    Sponsor Name:Sigrun Kjøtrød
    Full Title: Metformin treatment before IVF/ICSI in normal weight women with polycystic ovarian syndrome. A European, prospective, randomised, double blind, multicenter study.
    Medical condition: Polycystic ovary syndrome (PCOS) is a disorder characterized by polycystic ovaries, oligo-amenorrhea and hyperandrogenism. It is the most common endocrine disorder in women of fertile age. PCOS wom...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) FI (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000228-20 Sponsor Protocol Number: 16012020001 Start Date*: 2020-08-28
    Sponsor Name:Medical University of Graz
    Full Title: Probiotic dietary Intervention in Polycystic Ovary Syndrome – A Randomized Controlled Trial
    Medical condition: Polycystic Ovary Syndrome (PCOS) is a hormonal and metabolic disorder affecting up to 20 percent of women worldwide, depending on diagnostic criteria. A very common definition of PCOS based on the ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016241-25 Sponsor Protocol Number: ERI2005VER Start Date*: 2010-06-15
    Sponsor Name:VERISFIELD (UK) LTD, GREEK BRANCH
    Full Title: MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARATIVE WITH THE REFERENCE PRODUCT CLINICAL STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF THE THERAPY WITH THE COMBINATION ERYTHROMYCIN-ISOTRETINOIN/VER...
    Medical condition: MILD TO MODERATE ACNE (ACNE VULGARIS)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000461-18 Sponsor Protocol Number: PCOS/DM/1 Start Date*: 2005-03-31
    Sponsor Name:University of Hull
    Full Title: Study to Determine if The Cardiovascular risk indices in Type 2 diabetes are similar for Polycystic Ovarian Syndrome, and whether they may be modified by Therapy
    Medical condition: This is a randomised parallel controlled trial between patients with type 2 diabetes and those with polycystic ovarian syndrome. Patients will either be randomised to metformin or Pioglitazone.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000435-18 Sponsor Protocol Number: PCOS/IGT/1 Start Date*: 2005-03-31
    Sponsor Name:University of Hull
    Full Title: Study to Determine if The Cardiovascular risk indices in Impaired Glucose Tolerance are similar for Polycystic Ovarian Syndrome, and whether they may be modified by Therapy
    Medical condition: This is a randomised parallel controlled trial between patients with impaired glucose tolerance and those with polycystic ovarian syndrome. Patients will either be randomised to metformin or Piogli...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001373-16 Sponsor Protocol Number: CLIK066X2205 Start Date*: 2017-09-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome
    Medical condition: polycystic ovary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10036050 Polycystic ovary LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003862-15 Sponsor Protocol Number: 2013-601 Start Date*: 2013-11-19
    Sponsor Name:Jens Faber
    Full Title: Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis
    Medical condition: Polycystic Ovary Syndrome (PCOS), especialy signs of early cardiovascular disease in women with PCOS.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003630-33 Sponsor Protocol Number: ERGO45359 Start Date*: 2019-01-23
    Sponsor Name:University of Southampton
    Full Title: Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe p...
    Medical condition: Acne of sufficient severity to warrant treatment with oral antibiotics.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-010288-17 Sponsor Protocol Number: 1516 Start Date*: 2009-07-13
    Sponsor Name:Karolinska Hospital
    Full Title: Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS)
    Medical condition: Polycystic ovary syndrome (PCOS) is the most common hormonal aberration in women of fertile age, with a prevalence of 5-10%, and is associated with chronic anovulation, hyperandrogenism and PCO mo...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015729-35 Sponsor Protocol Number: PCOS&Niacin Start Date*: 2009-11-23
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS)
    Medical condition: Polycystic ovary syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005470-69 Sponsor Protocol Number: SPON CU 153 Start Date*: 2007-08-16
    Sponsor Name:Cardiff University
    Full Title: A randomised, double-blind, placebo-controlled crossover trial of the effects of metformin therapy on vascular and metabolic risk in young women with polycystic ovary syndrome.
    Medical condition: Polycystic Ovary Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000285-36 Sponsor Protocol Number: PILOTINA Start Date*: 2006-04-01
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Protocol for a pilot study examining the impact of Metformin use on serum testosterone levels in postmenopausal women
    Medical condition: HYPERANDROGENISM
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052547 HLGT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004604-20 Sponsor Protocol Number: AGO/2018/007 Start Date*: 2019-12-03
    Sponsor Name:Ghent University Hospital
    Full Title: Myo-inositol versus clomiphene citrate as first line treatment for ovulation induction in PCOS
    Medical condition: Polycystic ovary syndrome (PCOS)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004250-18 Sponsor Protocol Number: PIAII Start Date*: 2016-02-19
    Sponsor Name:Karolinska Institutet
    Full Title: Acupuncture or Metformin for Insulin Resistance in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial
    Medical condition: Polycystic ovary syndrome (PCOS) affects 10 to 15% of all women and is the most common female endocrine and metabolic disorder during the reproductive years. PCOS is characterized by anovulation, h...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    18.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004447-35 Sponsor Protocol Number: version 1, 05/08/2006 Start Date*: 2006-09-20
    Sponsor Name:Hull and East Yorkshire Hospital Trust
    Full Title: Biological Variation of Insulin Resistance, Testosterone and Cardiovascular Risk Factors In Women with Polycystic Ovarian Syndrome: modification with Rimonabant compared to Metformin.
    Medical condition: Patients with Polycystic Ovary Syndrome and body mass index above 30 kg/m2
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036049 Polycystic ovaries LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:42:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA